MINNEAPOLIS, Aug. 10, 2010 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy™ technology to urologists to provide a durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), announced Christopher R. Barys has joined the Board of Directors effective August 6, 2010.
"We are pleased and excited to welcome Chris Barys to the Urologix Board," stated Mr. Warren. "In addition to his senior leadership and operating experience in medical technology companies, Chris complements existing Urologix Board expertise with his strong background in Sales and Marketing - a key element to the Company's continued effort to firmly establish Cooled ThermoTherapy™ as a first-line, definitive therapeutic alternative to BPH medications."
Mr. Barys has spent 20 years in the medical field and was most recently Chief Operating Officer at FlowCardia - a company providing endovascular tools for crossing chronic total occlusions (CTOs) in the leg and coronary arteries. Chris has spent over 15 years in the interventional space including senior positions at Edwards LifeSciences as Vice President of Leadership Development and as Vice President of Sales and Marketing for the Peripheral Vascular Systems business for Edwards where he had broad responsibility for the fastest growing franchise within the company. Previously, Chris held senior Sales and Marketing positions at Johnson & Johnson's Cordis Cardiology division, Boston Scientific's Vascular Division and U.S. Surgical. Chris received his BS degree in Marketing from Northern Illinois University.Mr. Barys stated, "I am pleased to be joining such an experienced board and look forward to providing leadership support. There are so many different treatment options offered for BPH that the average patient becomes very confused about what might be the most efficacious treatment. Cooled ThermoTherapy™ has established itself as one of the most successful and efficacious treatment options for patients."